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Abstract
Background: HIV-1 replication depends on a delicate balance between cellular co-factors and antiviral restriction factors.
Lens epithelium-derived growth factor (LEDGF/p75) benefits HIV, whereas apolipoprotein B mRNA-editing catalytic
polypeptide-like 3G (APOBEC3G), tripartite motif 5alpha (TRIM5a), and tetherin exert anti-HIV activity. Expression levels of
these proteins possibly contribute to HIV-1 resistance in HIV-1-exposed populations.
Methodology/Principal Findings: We used real-time PCR and flow cytometry to study mRNA and protein levels respectively
in PBMC and PBMC subsets. We observed significantly reduced LEDGF/p75 protein levels in CD4+ lymphocytes of HIV-1-
exposed seronegative subjects relative to healthy controls, whereas we found no differences in APOBEC3G, TRIM5a,o r
tetherin expression. Untreated HIV-1-infected patients generally expressed higher mRNA and protein levels than healthy
controls. Increased tetherin levels, in particular, correlated with markers of disease progression: directly with the viral load
and T cell activation and inversely with the CD4 count.
Conclusions/Significance: Our data suggest that reduced LEDGF/p75 levels may play a role in resistance to HIV-1 infection,
while increased tetherin levels could be a marker of advanced HIV disease. Host factors that influence HIV-1 infection and
disease could be important targets for new antiviral therapies.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) interacts with
many cellular host proteins during its replication cycle [1–3]. Some of
these proteins are required for HIV-1 replication while others exhibit
antiviral activity. Lens epithelium-derived growth factor p75
(LEDGF/p75) [4] is a cellular co-factor, whereas apolipoprotein B
mRNA-editing catalytic polypeptide-like 3G (APOBEC3G, A3G)
[5], tripartite motif 5alpha (TRIM5a) [6], and tetherin (BST2,
CD317, HM1.24) [7] are cellular factors with distinct antiviral
activities. The main working mechanisms of these factors can be
summarized as follows. LEDGF/p75 assists in the integration of viral
cDNA into specific regions of the host’s genetic material [8,9].
APOBEC3G inhibits HIV replication by inducing G-to-A hypermu-
tation of the viral HIV-1 genome during reverse transcription [5,10].
TRIM5a structurally disorders the retroviral capsid, leading to the
interruption of the natural ‘‘uncoating’’ process in a species-specific
manner [11,12]; and was recently described to promote innate
immune signaling [13]. Tetherin, finally, inhibits HIV release by
tethering newly formed retrovirus particles to the cell membrane [7].
The significance of these four proteins as possible correlates of
protection against HIV-1 remains to be determined. Several
studies on peripheral blood mononuclear cells (PBMC) have found
that APOBEC3G mRNA levels correlate positively with the CD4
count and negatively with the viral load of untreated HIV-1-
infected subjects [14–16], suggesting that APOBEC3G contributes
to the control of HIV-1 infection. However, other studies did not
find such correlations for APOBEC3G [17–19] or TRIM5a [20]
mRNA. In addition, certain studies compared the expression of
APOBEC3G or TRIM5a between distinct study populations like
untreated HIV-1-infected subjects, healthy controls, and HIV-1-
exposed seronegative individuals. Some studies observed lower
mRNA expression levels of APOBEC3G [14,17,19] or TRIM5a
[20] in untreated HIV-1-infected subjects compared to healthy
controls, although the opposite was also found for APOBEC3G
[15]. APOBEC3G mRNA and protein expression levels were also
studied respectively in PBMC and PBMC-subsets (CD4+ and
CD8+ lymphocytes, and CD14+ monocytes) of HIV-1-exposed
seronegative subjects relative to healthy controls [16,19,21]. Here
too, conflicting data were obtained, showing either similar [19] or
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seronegative subjects relative to healthy controls.
In the present study, we investigated mRNA and protein
expression levels of the 4 HIV-1-related factors LEDGF/p75,
APOBEC3G, TRIM5a, and tetherin in HIV-1-exposed seroneg-
ative subjects, healthy controls, untreated HIV-1-infected subjects,
and antiretroviral therapy-treated HIV-1-infected subjects. HIV-
1-exposed seronegative subjects are individuals who remain HIV-1
seronegative despite frequent and unprotected exposure to HIV,
and are observed in cohorts of commercial sex workers, men
having sex with men, intravenous drug users, and discordant
couples [22]. In this study, HIV-1-exposed seronegative subjects
were enrolled from a Senegalese cohort of HIV-1 serodiscordant
couples. Real-time quantitative polymerase chain reaction (qPCR)
was applied to study mRNA expression in PBMC. Protein
expression levels were determined simultaneously in different
PBMC subsets by flow cytometry. We hypothesized that
expression levels of the above-mentioned proteins may contribute
to the putative in vivo HIV-1 restriction in HIV-1-exposed
seronegative subjects.
Materials and Methods
Ethics Statement
The study was approved by the Internal Review Board of the
Institute of Tropical Medicine (Antwerp, Belgium) and by the
Ethical Committees of the Senegalese Ministry of Health (Dakar,
Senegal) and the University Hospital of Antwerp (Belgium). All
study subjects gave written informed consent prior to enrollment.
Study population
This study was conducted on a cohort of heterosexual couples
recruited at the Department of Infectious Diseases at the Fann
University Teaching Hospital, Dakar, Senegal, as previously
described [23]. Twenty three HIV-1 exposed seronegative subjects
(HESN) in HIV-1 serodiscordant couples, 23 healthy controls
(HC) in HIV-1-negative seroconcordant monogamous couples,
and 45 HIV-1-infected patients in HIV-1 serodiscordant or HIV-
1-positive seroconcordant couples were studied. Within the group
of 45 HIV-1-infected patients, 9 patients were untreated HIV-1-
infected subjects (HIV-UT) and 36 patients were antiretroviral
therapy-treated HIV-1-infected subjects (HIV-ART). All couples
had a sexual relationship of at least 7.5 years. HESN and HC were
matched for gender. Blood samples and standard questionnaires
with information on socio-demographics and sexual behavior were
collected. Male condom provision and sexual risk reduction
counseling were provided during every visit.
Sample collection and processing
Whole blood samples were collected in EDTA tubes. CD4+ T
cell counts and T cell activation levels were determined in fresh
whole blood using CD3, CD4, CD8, and CD38 fluorochrome-
labeled antibodies and a FACSCalibur flow cytometer (BD
Biosciences) like previously reported [23]. In this article, the T
cell activation status is determined by the percentage of CD38+
cells among the CD8+ T cells. Plasma and PBMC were separated
from fresh whole blood, frozen down at 280uC and in liquid
nitrogen, respectively, and shipped to Belgium. HIV and HSV-2
(Herpes simplex virus type 2) status were determined in plasma by
ELISA. HIV-1 viral loads were quantified in plasma by the
Amplicor HIV-1 Monitor assay, version 1.5 (Roche Diagnostics
GmbH). PBMC were thawed, washed twice, and counted prior to
mRNA and protein expression analysis.
RNA extraction, DNase treatment and reverse
transcription
PBMC samples were dissolved in TRIzolH Reagent (Invitrogen)
and stored at 280uC for less than three months. Total RNA was
isolated according to the manufacturer’s instructions (Invitrogen).
Removal of genomic DNA was performed with the DNA-free Kit
(Ambion) following the manufacturer’s protocol. Additional wash
steps, once with 200 ml isopropanol (in the presence of 0.7 mlo f
glycogen) and twice with 75% ethanol, were performed to remove
traces of contaminants. The NanoDrop ND-1000 spectrophotom-
eter (Thermo Scientific) was used to quantify total RNA levels.
Total DNase-treated RNA was stored at 280uC for less than one
month. The iScript cDNA synthesis Kit (Bio-Rad Laboratories
NV-SA) was applied to 400 ng of total DNase-treated RNA
following the manufacturer’s instructions. In parallel, 100 ng of
the same RNA was dissolved in RNase/DNase-free water (no-RT
control) at the same final concentration (20 ng/10.5 ml) as the RT
(reverse transcribed) samples. Both RT and no-RT samples were
stored at 280uC for less than one month. For each sample, the
difference in quantification cycle (Cq)-value between RT and no-
RT samples was higher than 10. During optimization of the qPCR
protocol, RNA quality was evaluated by RNA gel electrophoresis
(1% agarose gel). The 18S and 28S fragments were visualized with
GelRed (VWR) versus a 1-kb DNA ladder (Invitrogen) and were
observed in the expected 1:2 ratio on representative samples.
Real-time PCR
Messenger RNA (mRNA) expression levels were quantified by
real-time PCR using the Bio-Rad CFX96 system and SYBR
Green mix (Bio-Rad). Target-specific primers were designed using
the Harvard website: http://pga.mgh.harvard.edu/primerbank/,
except for TRIM5a and TBP, for which Primer3 software (v.0.4.0)
was used. Specificity was tested using BLAST (NCBI). All primer
pairs, except for TRIM5a, could be designed to span at least one
intron. Name, GeneID, primer sequences, exon localization and
amplicon length are listed in Table 1. The primer mixes were
prepared by combining Forward (Fw) and Reverse (Re) Primers
(Eurogentec), both at a concentration of 2 pmol/ml. Each
optimized 25 ml reaction contained 12.5 ml of iQ SYBR Green
Supermix (Bio-Rad), 2 ml of the primer mix and 5, 10 or 20 ng of
the cDNA template at a volume of 10.5 ml. Each assay included, in
triplicate, a standard curve, a no-template control (water), the RT
samples, and, in the case of TRIM5a, the no-RT samples. The
following subsequent heating steps were included as PCR cycling
conditions: 50uC (10 min), 95uC (3 min), 40 cycles of 95uC (10 s)
and 60uC (30 s) with fluorescence capturing following each cycle,
95uC (10 s), and melting curve acquisition with fluorescence
capturing every 5 s during a temperature increase in 0.5uC
increments from 65uCt o9 5 uC. The amplicon length of the PCR
product was validated by 2% agarose DNA gelelectrophoresis.
PCR products were visualized with GelRed (VWR) versus a 100-
bp DNA ladder (Invitrogen).
mRNA data analysis
The obtained results (Cq-values) were exported from the Bio-
Rad CFX Manager version 1.5 and imported into qbase
PLUS
software, version 1.5, from BioGazelle (Ghent, Belgium) following
baseline subtraction and manual threshold matching. The
GeNorm applet selected the reference genes B2M and GAPDH
out of five genes (UBC, B2M, GAPDH, RPL13A, TBP) as the most
stably expressed across the different study populations (25 samples,
all applied in triplicate). Both reference genes were used to
normalize target gene expression in the qbase
PLUS software. For
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Caucasian healthy control was used. Cq-values were converted
into relative expression values taking into account amplification
efficiencies, inter-run variations, and normalization factors.
Outliers were excluded when a difference of more than 1.0 was
registered in the Cq-values. Finally, CNRQ (Calibrated Normal-
ized Relative Quantity) values were exported from the qbase
PLUS
software and statistically investigated.
Table 1. Primers used for reverse transcriptase quantitative polymerase chain reaction (RT-qPCR).
GeneID Primer Sequence 59 to 39 Exon localization Amplicon length
Genes of interest
LEDGF/p75 11168 Fw
*
Re
{
TCGACTTCAAAGGATACATGCTG
GAGCTTGTTGCATTGTGACCT
12
13
122
APOBEC3G 60489 Fw
Re
TCAGAGGACGGCATGAGACTT
TGGAGCCTGGTTGCATAGAAA
5
5a n d6
107
TRIM5alpha 85363 Fw
Re
TGCTGGCTTCCAACCTGAT
ACAGAGAGGGGCACAATGAA
8
8
165
Tetherin (BST2) 684 Fw
Re
GAGTGTCGCAATGTCACCCAT
GGAAGCCATTAGGGCCATCAC
1
1a n d2
120
Reference genes
UBC
{ 7316 Fw
Re
ATTTGGGTCGCAGTTCTTG
TGCCTTGACATTCTCGATGGT
1
2
123
B2M
1 567 Fw
Re
GGCTATCCAGCGTACTCCAAA
CGGCAGGCATACTCATCTTTTT
1a n d2
2
246
GAPDH
I 2597 Fw
Re
TGTTGCCATCAATGACCCCTT
CTCCACGACGTACTCAGCG
3
5
202
RPL13A
" 23521 Fw
Re
CGAGGTTGGCTGGAAGTACC
CTTCTCGGCCTGTTTCCGTAG
7
8
121
TBP
# 6908 Fw
Re
ACCCAGCAGCATCACTGTTT
CCAAGCCCTGAGCGTAAG
1a n d2
2
200
*Forward primer,
{Reverse primer,
{Ubiquitin C,
1Beta-2-Microglobulin,
IGlyceraldehyde 3-phosphate dehydrogenase,
"60S ribosomal protein L13a, and
#TATA-binding protein.
doi:10.1371/journal.pone.0033934.t001
Table 2. Characteristics of HIV-exposed seronegative, HIV-1-infected, and healthy control subjects included in the study.
HC
*
(n=23)
HESN
{
(n=23)
HIV-UT
{
(n=9)
HIV-ART
1
(n=36) p-value
HESN vs. HC HIV-UT vs. HC HIV-ART vs. HIV-UT
Age, years 43
(37–46)
41
(33–47)
46
(37–51)
44
(36–51)
0.409 0.449 0.955
Gender (% male) 47.8 43.5 88.9 72.2 0.770 0.036 0.303
CD4 count (cells/ml) 789
(703–1090)
738
(548–891)
228
(133–337)
334
(195–412)
0.215 ,0.001 0.294
Number of sexual contacts
per month
8
(3–12)
5
(4–8)
5
(4–11)
7
(4–8)
0.164 0.831 0.831
Duration of sexual relation, years 12
(8–19)
11
(8–18)
11
(9–18)
10
(8–16)
0.938 0.866 0.540
Condom use (% always) 0 61 44 50 ,0.001 0.001 0.768
HSV-2 serostatus (% HSV-2 positive) 22 45 78 59 0.095 0.004 0.301
Data are median (interquartile range) values or percentages if indicated.
*Healthy controls,
{HIV-exposed seronegatives,
{therapy-naı ¨ve HIV-1-infected subjects,
1antiretroviral therapy-treated HIV-1-infected subjects. P-values (Mann Whitney U) below 0.05 are in bold.
doi:10.1371/journal.pone.0033934.t002
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The protein expression levels of LEDGF/p75, APOBEC3G,
TRIM5a, and tetherin were investigated in CD4+ T cell and
CD14+ monocyte subsets based on simultaneous intracellular
and/or cell surface staining of PBMC. The following reagents
were used: 0.1% bovine serum albumin (Acros Organics) and
0.05% sodium azide (Merck) in phosphate buffered saline (PBS,
Lonza) as washing buffer; Reagents A and B to fix and
permeabilize cells, respectively (Leucoperm kit, AbD Serotec);
primary mouse unlabeled antibody (isotype IgG1 and IgG2a) and
anti-LEDGF/p75 (IgG1) from BD Biosciences, anti-APOBEC3G
and anti-TRIM5a (both IgG1) from the AIDS Research and
Reference Reagent Program (Division of AIDS, NIAID, NIH),
and anti-tetherin (IgG2a) as kindly provided by Chugai Pharma-
ceutical Co., Japan; secondary FITC-labeled antibody (BD
Biosciences); normal mouse serum (eBioscience); membrane
antibodies anti-CD4-PerCP, anti-CD45RO-APC, anti-CD38-PE,
anti-CD14-APC, and anti-CD16-PE from BD Biosciences; and
1% paraformaldehyde (Sigma-Aldrich). LEDGF/p75, APO-
BEC3G, TRIM5a, and tetherin were analyzed using an in-house
optimized intracellular staining (ICS) protocol [24,25]. Cells were
washed (6306g, 10 min, RT), fixed (10 min, RT), washed twice,
permeabilized (30 min, 4uC), washed, incubated with primary
antibody (24 h, 4uC), washed twice, incubated with secondary
antibody supplemented with reagent B (30 min, 4uC), washed
twice, incubated with normal mouse serum (10 min, 4uC),
incubated with a membrane antibody cocktail (CD4/CD45RO/
CD38 or CD4/CD14/CD16 to study lymphocytes or monocytes,
respectively, 20 min, 4uC), washed twice, and dissolved in 1%
paraformaldehyde prior to data acquisition (FACSCalibur flow
Table 3. Expression levels of LEDGF/p75, APOBEC3G, TRIM5a, and tetherin in PBMC of HIV-exposed seronegative, HIV-infected,
and healthy control subjects.
HC
* HESN
{ HIV-UT
{ HIV-ART
1 p-value
HESN
vs. HC
HIV-UT
vs. HC
HIV-ART
vs. HIV-UT
mRNA expression N=20 N=20 N=9 N=31
LEDGF/p75 1.22
(0.88–1.50)
1.03
(0.83–1.36)
0.72
(0.53–1.11)
0.92
(0.70–1.10)
0.387 0.008 0.391
APOBEC3G 0.98
(0.79–1.23)
0.99
(0.86–1.25)
1.29
(1.00–1.38)
0.96
(0.83–1.22)
1 0.172 0.078
TRIM5a 1.08
(0.79–1.42)
0.85
(0.74–1.27)
1.22
(0.92–1.89)
0.78
(0.65–1.18)
0.372 0.370 0.016
Tetherin 1.12
(0.88–1.36)
1.10
(0.96–1.29)
1.46
(1.14–1.85)
0.99
(0.78–1.06)
1 0.027 ,0.001
Protein expression N=23 N=23 N=9 N=36
CD4+ lymphocytes
LEDGF/p75 113.10
(97.62–126.05)
98.80
(77.95–110.13)
121.91
(85.58–53.40)
106.85
(94.77–122.80)
0.022 0.516 0.371
APOBEC3G 39.61
(35.48–42.93)
38.01
(31.08–44.88)
39.68
(36.58–47.88)
40.64
(35.53–47.08)
0.613 0.572 0.691
TRIM5a 107.57
(96.87–123.01)
112.80
(93.67–125.22)
126.13
(100.47–156.08)
115.15
(100.26–134.41)
0.939 0.148 0.427
Membrane tetherin 4.16
(3.71–4.68)
4.35
(3.94–4.81)
6.55
(5.34–9.29)
4.77
(4.03–5.19)
0.733 ,0.001 ,0.001
Total tetherin 5.32
(4.64–6.74)
5.33
(4.43–6.54)
10.73
(7.20–18.52)
5.88
(5.43–6.90)
0.809 0.003 0.004
CD14+ monocytes
LEDGF/p75 49.26
(40.55–70.39)
45.51
(36.73–71.27)
77.05
(62.22–86.85)
45.65
(40.94–59.45)
0.750 0.005 0.002
APOBEC3G 102.09
(81.37–128.12)
98.62
(80.19–13.40)
123.28
(111.52–172.55)
105.30
(90.89–116.28)
0.328 0.031 0.002
TRIM5a 280.38
(234.04–335.57)
283.79
(235.40–332.42)
398.98
(317.44–513.08)
287.94
(257.72–331.20)
0.869 0.005 0.002
Membrane tetherin 1.62
(0.00–6.67)
2.42
(0.00–4.95)
11.77
(6.38–21.86)
4.78
(1.19–7.17)
0.894 0.002 0.005
Total tetherin 49.28
(40.00–65.42)
49.84
(40.99–55.70)
79.48
(59.27–113.97)
46.13
(38.27–50.87)
0.956 0.003 ,0.001
Data are median (interquartile range) values depicting Calibrated Normalized Relative Quantity (CNRQ-)values for mRNA and Median Fluorescence Intensity (MFI-)values
for protein expression.
*Healthy controls,
{HIV-exposed seronegatives,
{therapy-naı ¨ve HIV-1-infected subjects,
1antiretroviral therapy-treated HIV-1-infected subjects. P-values (Mann Whitney U) below 0.05 are in bold. Of note, due to sample loss during RNA extraction, data on
mRNA expression were gathered for slightly less study subjects.
doi:10.1371/journal.pone.0033934.t003
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PBMC were processed according to the protocol above with a 30-
min anti-tetherin incubation at 4uC, without fixation or permea-
bilization steps. In general, at least 25000 and 50000 events were
respectively measured to study expression patterns in CD4+
lymphocytes and CD14+ monocytes. Data analysis with CellQuest
Pro Software (BD Biosciences) produced median fluorescence
intensity (MFI) values, reflecting the median amount of bound
Figure 1. Correlations between mRNA and protein levels. Correlation patterns were studied in all study subjects between mRNA (CNRQ-
values, x-axis) and protein (MFI-values, y-axis) levels of (A) LEDGF/p75 (LGF), (B) APOBEC3G (A3G), (C) TRIM5a (T5a), (D) membrane tetherin
(memTeth), and (E) total tetherin (totTeth). mRNA levels were studied in PBMC while protein levels were analyzed in lymphocytes (Ly, left), CD4+
lymphocytes (CD4Ly, middle), and CD14+ monocytes (CD14Mo, right). CNRQ-values refer to Calibrated Normalized Relative Quantity of mRNA
expression levels and MFI-values refer to Median Fluorescence Intensity of protein expression levels. Spearman’s Rho (Rho) and p-values were
obtained by non-parametric Spearman’s rank correlation tests. P-values below 0.05 are in bold.
doi:10.1371/journal.pone.0033934.g001
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MFI-values were corrected for non-specific background staining
by subtracting isotype MFI-values.
Statistical analyses
Differences in expression levels between individuals of different
study groups were investigated with non-parametric Mann-
Whitney U tests. Correlation analyses were performed using
non-parametric Spearman’s rank correlation tests. Observations
were considered statistically significant when p,0.05. Statistical
analyses were performed with SPSS version 17.0, and graphs were
drawn with GraphPad Prism, version 5.
Results
Study population
Twenty three HIV-1-exposed seronegative subjects (HESN), 23
healthy controls (HC), and 45 HIV-1-infected patients were
studied. Nine HIV-1-infected patients were untreated (HIV-UT)
and 36 were antiretroviral therapy-treated (HIV-ART). Several
parameters like age, gender, duration of the sexual relationship,
CD4 count, number of sexual contacts per month, condom use,
and HSV-2 serostatus were compared between HESN and HC,
HIV-UT and HC, and HIV-ART and HIV-UT (Table 2). The
HC subjects were in a monogamous relationship for at least 7.5
years at the time of enrollment. They reported a significantly lower
percentage of condom use. HIV-1-infected subjects were more
often male individuals. Therapy-naı ¨ve HIV-1 infected subjects
(HIV-UT) showed significantly lower CD4 count levels than HC,
and a higher prevalence of HSV-2 seropositivity.
Differences in mRNA expression in PBMC
The mRNA expression levels of LEDGF/p75, APOBEC3G,
TRIM5a, and tetherin were analyzed for all study subjects in
PBMC by real-time qPCR (Table 3). None of the genes displayed
a significant difference in mRNA expression between HESN and
HC. HIV-UT showed significantly lower levels of LEDGF/p75
(p=0.008) and higher levels of tetherin (p=0.027) than HC.
Additionally, higher expression levels of APOBEC3G (p=0.078),
TRIM5a (p=0.016), and tetherin (p,0.001) were observed in
HIV-UT relative to HIV-ART subjects.
Differences in protein expression in lymphocytes and
monocytes
Next, we analyzed protein expression levels of LEDGF/p75,
APOBEC3G, TRIM5a, and tetherin in CD4+ lymphocytes and
CD14+ monocytes by a novel intracellular staining assay [25].
Expression of LEDGF/p75 was found to be significantly reduced
(p=0.022) in CD4+ lymphocytes of HESN compared to HC
(Table 3). APOBEC3G, TRIM5a, and tetherin protein levels were
similar for HESN and HC. HIV-UT showed significantly higher
tetherin levels in CD4+ lymphocytes and significantly higher levels
of all four proteins in CD14+ monocytes compared to HC and
HIV-ART.
Correlations between mRNA and protein levels
Subsequently, we correlated mRNA levels in PBMC with
protein levels specifically in lymphocytes and monocytes within the
entire study population including HESN, HC, HIV-UT, and
HIV-ART subjects (Figure 1). For most HIV-related host factors,
we observed a significant positive correlation between mRNA and
protein level as was most prominent for total tetherin, whereas no
significant correlations were observed for LEDGF/p75.
Correlates of reduced LEDGF/p75 in HESN
To obtain insight into the possible role played by LEDGF/p75
in resistance to HIV-1 infection, we studied the reduced LEDGF/
p75 expression levels in HESN considering the duration of the
sexual relation, the number of sexual contacts per month, the
frequency of condom use, and the HSV-2 serostatus (Table 4). We
found that LEDGF/p75 expression levels were most reduced
among HESN with the highest number of sexual contacts per
month (p=0.065), whereas no difference in LEDGF/p75
expression was found in the HIV-1-negative control group
(Table 4).
Correlations between expression levels and T cell
activation
Finally, we investigated whether the observed differences in
mRNA and/or protein expression level could be correlated to T
cell activation levels and/or disease status (viral load and CD4
count). Whereas no significant difference was observed in CD4+ T
cell activation level (% CD38+ cells among the CD4+ T cells,
Table 4. Expression levels of LEDGF/p75 versus HIV-1 risk/exposure parameters within different study populations of interest.
HC
* HESN
{
subgroup 1
a subgroup 2
b P-value subgroup 1 subgroup 2 P-value
Sexual contacts/month
(,
a vs $
b median value)
109.47
(98.59–124.73)
114.26
(94.84–137.76)
0.537 105.63
(95.04–112.09)
85.37
(74.88–104.96)
0.065
Duration of relation, years
(,
a vs $
b median value)
113.10
(99.57–141.30)
110.90
(89.88–124.04)
0.284 104.58
(73.50–111.30)
95.46
(81.66–112.71)
1.000
Condom use
(always
a vs not always
b)
- 110.23
(96.24–126.13)
ND 98.30
(69.33–111.37)
98.80
(81.66–112.66)
0.571
HSV-2 status
(negative
a vs positive
b)
110.23
(95.70–124.73)
123.96
(96.80–132.58)
0.502 98.30
(76.20–110.11)
101.50
(85.31–126.40)
0.468
*Healthy controls,
{HIV-exposed seronegatives. Each HIV-1 risk/exposure parameter (left column) was used to split the study population in two subgroups (
a subgroup 1 versus
b
subgroup 2) based on a categorical or on a numerical parameter. Numerical parameters use median values (see Table 2) to split the study group in two subgroups
comparable in size. LEDGF/p75 expression levels are median (interquartile range) values. Within each study population, the P-value (Mann Whitney U) was calculated for
each HIV-1 risk/exposure parameter. ND: not determined as none of the subjects used a condom.
doi:10.1371/journal.pone.0033934.t004
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activation levels than HC (p=0.095) in Figure 2A. Reduced T cell
activation levels among HESN did not correlate with their
reduced LEDGF/p75 protein expression levels (p=0.970,
Figure 2B). Neither did we observe differences in LEDGF/p75
expression between distinct CD4+ lymphocytes based on
CD45RO (memory) or CD38 (activation) staining among HESN
(data not shown). In HIV-UT, T cell activation levels correlated
directly with TRIM5a (p=0.002) and tetherin (p=0.086) mRNA
levels, and inversely with LEDGF/p75 mRNA levels (p=0.037)
(data not shown). Membrane and total expression levels of
tetherin, in particular, correlated directly with T cell activation
and the viral load, and inversely with the CD4 count. These
correlations were most prominent for membrane tetherin as is
depicted in Figure 2C–E.
Discussion
In this study, we explored whether the expression of LEDGF/
p75, APOBEC3G, TRIM5a, and tetherin could play a role in
HIV-1 resistance. We studied mRNA levels in PBMC and protein
levels in CD4+ lymphocyte and monocyte subsets. We observed
significantly reduced levels of LEDGF/p75 protein expression in
the CD4+ T cells of HESN compared to those of HC, whereas
similar mRNA levels were found for both HESN and HC. Our
findings of lower levels of LEDGF/p75 in CD4+ lymphocytes of
HESN are in line with two recent HESN-studies showing reduced
gene expression levels of several host genes important for HIV
replication [26,27]. Lower LEDGF/p75 protein levels may cause
HIV-1 integration to occur less efficiently, thus contributing to
HIV-1 resistance in HESN subjects. This hypothesis is supported
by an in vitro experiment that found a direct correlation between
LEDGF/p75 expression levels and the efficiency of HIV-1
integration in the host genome [28]. Other studies, however,
reported that efficient knockdown or knock-out of LEDGF/p75 is
not sufficient to completely abolish HIV-1 replication [29–31],
suggesting that other factors may be needed in concert with
LEDGF/p75 to limit HIV integration in HESN subjects.
We observed no differences in mRNA or protein levels of
APOBEC3G, TRIM5a, or tetherin between HESN and HC.
These findings are at variance with previous reports showing
elevated APOBEC3G expression levels in HESN compared with
HC [16,21]. On the other hand, it has been suggested that
reduced exposure to HIV-1 results in comparable APOBEC3G
mRNA levels for HESN and HC over time [16]. In our HESN
population, most HIV-1-infected partners were treated with
antiretroviral therapy, and all couples received counseling to
promote condom use. Therefore, the lack of distinct expression
patterns may indeed result from the relatively low levels of HIV
exposure in our population. Moreover, Reddy et al [19] observed
similar levels of APOBEC3G mRNA between pre-infection values
of seroconverters and exposed persistently negative individuals,
suggesting that APOBEC3G mRNA levels would not contribute to
protection against HIV-1.
Figure 2. Statistical analyses within HESN and untreated HIV-1-
infected subjects. (A) Difference in CD4 (left) and CD8 (right) T cell
activation status (y-axis) between HESN and HC (x-axis). P-values were
obtained through the Mann Whitney U test. (B) Correlation pattern in
HESN subjects between LEDGF/p75 protein levels (LGF, y-axis) in CD4+
lymphocytes (CD4 Ly, left) and CD14+ monocytes (Mo, right) and T cell
activation status (x-axis). (C–E) The graphs depict correlation patterns in
CD4+ lymphocytes (CD4 Ly, left) and CD14+ monocytes (Mo, right) of
HIV-UT subjects between membrane tetherin protein levels (memTeth,
y-axis) and T cell activation status (x-axis, C), CD4 count (cells/mm
3) (x-
axis, D) and log viral load (x-axis, E). The subject’s general T cell
activation status is described by the percentage of CD38+ cells among
the CD8+ T cells (B,C). Spearman’s Rho (Rho) and p-values were
obtained by non-parametric Spearman’s rank correlation tests. P-values
below 0.05 are in bold. MFI=Median Fluorescence Intensity.
doi:10.1371/journal.pone.0033934.g002
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cantly lower LEDGF/p75 and higher tetherin mRNA levels than
HC, and higher APOBEC3G, TRIM5a, and tetherin mRNA
levels than HIV-ART. At protein level, HIV-UT expressed
significantly enhanced levels of tetherin in the lymphocytes and
of all four proteins in the monocytes. These data suggest that HIV-
1-infected subjects try to curb HIV-1 replication by increasing the
expression level of the antiviral restriction factors.
Interestingly, increased levels of tetherin in HIV-UT correlated
directly with T cell activation and the viral load and inversely with
the CD4 count. This finding suggests that tetherin is not capable of
controlling viral replication; instead it appears to be a marker of
advanced HIV disease in therapy-naı ¨ve HIV-1-infected patients.
Recently, Coleman et al [32] also reported increased tetherin
expression levels upon exposure to HIV-1 without it being capable
of restricting cell-to-cell spread of the virus. At least two other
studies support our observations by suggesting that the tetherin-
induced accumulation of unreleased virions at the cell membrane
could actually promote cell-to-cell spread, e.g., by enhancing
fusogenicity or regulating the integrity of the viral synapse [33,34].
In turn, accumulation of virus particles at the cell membrane may
trigger further increases in immune activation [35,36]. Thus,
tetherin may have a dual role during HIV-1 infection and disease.
As an innate mediator, tetherin may be involved in the control of
early or acute virus replication but it could become ineffective as
the infection progresses.
T-cell activation levels also correlated directly with mRNA
levels of TRIM5a but not with those of APOBEC3G; nevertheless
we expect that similar mechanisms like those observed for tetherin
are involved here. Indeed, type I interferons which are induced
upon viral replication are known to upregulate APOBEC3G
[15,37–39], TRIM5a [40,41], and tetherin [36,42]. High-level
interferon receptor expression on monocytes [21] may explain
why our data showed relatively higher increases of APOBEC3G,
TRIM5a, and tetherin in monocytes than in lymphocytes.
Intriguingly, HIV-UT expressed reduced mRNA levels in
PBMC and elevated protein levels in monocytes for LEDGF/
p75, relative to HC. The mRNA levels correlated inversely
(p=0.05; Rho=20.667) and the protein levels tended to correlate
directly (p=0.170; Rho=0.5) with the viral load of these patients
(data not shown). These correlations suggest that LEDGF/p75
expression may also account for disease progression in HIV-UT,
supporting recently described observations by Madlala et al [27].
Parallel to type I interferon induction, viral replication induces the
production of several cytokines and chemokines amongst which
Tumor Necrosis Factor alpha (TNF-a), which can induce
LEDGF/p75 levels [43,44]. Of note, long period or high level
exposure to TNF-a makes LEDGF/p75 levels decrease again [44],
which may play a role in the difference seen between LEDGF/p75
mRNA and protein levels.
Apart from the reasoning in the previous paragraph, mRNA
and protein levels may differ as mRNA is not necessarily translated
into (functional) protein [45], and external factors may act
differently upon protein and mRNA levels [39,46]. Our data
e.g. also show a difference in mRNA versus protein expression for
LEDGF/p75 in HESN (Figure 1A). Nevertheless, we did observe
some correlations between protein levels in (CD4+) lymphocytes,
and mRNA levels in PBMC which are predominantly composed
of lymphocytes (Figure 1B–E). Of note, due to the limited number
of CD4+ cells in HIV-1-infected subjects, we were obliged to work
with PBMC for quantification of mRNA levels. On the other
hand, the flow cytometry based method allowed us to investigate
protein levels in PBMC subsets. As earlier studies also focused on
mRNA levels in PBMC, we could easily compare our results with
these results previously obtained. For example, our data supported
that APOBEC3G mRNA levels are similar for HESN and HC
[19]. On the other hand, in literature, limited information is
forehand regarding protein expression in particular cell-types
while proteins are considered to be of greater relevance in the
‘‘direct’’ fight against HIV-1 infection as they are the ‘‘work
horses’’ of the cell.
In summary, we observed significantly lower levels of LEDGF/
p75 in CD4+ lymphocytes of HESN subjects, suggesting that
LEDGF/p75 may play a role in the in vivo resistance to HIV-1
infection. Untreated HIV-1-infected patients showed increased
levels of the antiviral proteins APOBEC3G, TRIM5a, and
tetherin, with tetherin in particular as a possible marker of
advanced HIV disease. Future studies of LEDGF/p75 expression
in other populations of HESN subject will be required to confirm
our findings. Understanding the role of HIV-1-related host factors
in HIV-1 susceptibility and disease could be of great interest for
the development of future antiviral therapies.
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